Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China · Delayed Price · Currency is CNY 21.32
-0.21 (-0.98%)
Feb 27, 2026, 3:00 PM CST
SHA:600671 Revenue
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had revenue of 55.34M CNY in the quarter ending September 30, 2025, a decrease of -15.03%. This brings the company's revenue in the last twelve months to 251.56M, up 56.88% year-over-year. In the year 2024, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had annual revenue of 217.30M with 78.44% growth.
Revenue (ttm)
251.56M
Revenue Growth
+56.88%
P/S Ratio
10.32
Revenue / Employee
694.91K
Employees
362
Market Cap
2.60B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 217.30M | 95.52M | 78.44% |
| Dec 31, 2023 | 121.78M | 12.87M | 11.82% |
| Dec 31, 2022 | 108.91M | -38.16M | -25.95% |
| Dec 31, 2021 | 147.07M | -59.56M | -28.82% |
| Dec 31, 2020 | 206.63M | -90.45M | -30.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Int'l Group | 33.54B |
| Zhejiang Zhenyuan Share | 2.67B |
| Shanghai Shenqi Pharmaceutical Investment Management | 1.88B |
| Chongqing Lummy Pharmaceutical | 771.02M |
| Hangzhou Minsheng Healthcare | 744.06M |
| Hubei Guangji Pharmaceutical | 605.87M |
| Hangzhou Bio-Sincerity Pharma-Tech | 590.33M |
| Zhejiang Haisen Pharmaceutical | 510.33M |